The Drug Affinity Complex modification of CJC-1295 works by attaching the peptide to endogenous albumin in the bloodstream, using albumin's naturally long half-life (~19 days) as a reservoir. Once bound, CJC-1295 DAC is slowly released, maintaining low-level but continuous GHRH receptor stimulation across the entire week from a single injection.

This sustained stimulation profile is fundamentally different from CJC-1295 No DAC. Rather than producing natural pulsatile GH bursts, DAC produces a continuous 'GH bleed' — less physiologic, but potentially advantageous for research goals prioritizing consistent IGF-1 elevation over week-long periods. Some researchers combine a small weekly dose of DAC with daily Ipamorelin for both sustained baseline and pulsatile peaks.